Valuation: InnoCan Pharma Corporation

Capitalization 42.34M 40.89M 38.71M 34.12M 60.6M 3.68B 67.6M 462M 171M 1.53B 159M 156M 6.55B P/E ratio 2022
-10.5x
P/E ratio 2023 -12.8x
Enterprise value 38.49M 37.17M 35.19M 31.01M 55.09M 3.35B 61.45M 420M 155M 1.39B 144M 141M 5.96B EV / Sales 2022
15,502,543x
EV / Sales 2023 4,606,415x
Free-Float
77.49%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 week+2.70%
Current month+18.75%
1 month-2.56%
3 months-5.00%
6 months-13.64%
Current year-9.52%
More quotes
1 week
0.18
Extreme 0.18
0.19
1 month
0.16
Extreme 0.16
0.20
Current year
0.16
Extreme 0.16
0.21
1 year
0.16
Extreme 0.16
0.33
3 years
0.16
Extreme 0.16
0.74
5 years
0.05
Extreme 0.05
1.65
10 years
0.05
Extreme 0.05
1.65
More quotes
Director TitleAgeSince
Chief Tech/Sci/R&D Officer 72 -
Chief Executive Officer - 2018-05-30
Director of Finance/CFO - 2019-02-19
Manager TitleAgeSince
Chairman 60 2019-09-24
Director/Board Member - 2018-05-30
Director/Board Member - 2019-09-29
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
0.00%+2.70%-38.71%-73.97% 38.51M
+0.92%+3.66%+18.41%+270.31% 786B
-0.56%+0.37%-1.64%-7.42% 374B
-1.87%-9.06%-30.61%+79.60% 361B
+0.61%+0.65%+11.52%+35.91% 341B
+1.30%+2.82%+29.45%-13.56% 256B
+1.63%+1.65%+24.79%+42.94% 227B
-1.01%-4.46%-31.65%+11.78% 217B
-0.37%-0.32%+10.66%+23.00% 211B
-0.54%-4.14%+0.21%+29.30% 159B
Average +0.07%+0.66%-0.76%+39.79% 293.19B
Weighted average by Cap. -0.02%+0.95%+5.23%+91.76%
See all sector performances

Financials

2022 2023
Net sales 2.56 2.47 2.34 2.06 3.66 222.39 4.09 27.93 10.31 92.41 9.59 9.4 396.07 13.66 13.19 12.48 11 19.55 1.19K 21.8 149.05 55.01 493.19 51.2 50.17 2.11K
Net income -3.76M -3.63M -3.44M -3.03M -5.39M -327M -6.01M -41.08M -15.16M -136M -14.11M -13.83M -583M -4.7M -4.54M -4.3M -3.79M -6.73M -408M -7.5M -51.3M -18.93M -170M -17.62M -17.26M -727M
Net Debt -4.91 -4.74 -4.49 -3.96 -7.03 -426.97 -7.84 -53.62 -19.79 -177.42 -18.42 -18.05 -760.41 -3.85 -3.72 -3.52 -3.1 -5.51 -334.76 -6.15 -42.04 -15.52 -139.11 -14.44 -14.15 -596.2
More financial data * Estimated data
Logo InnoCan Pharma Corporation
Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.
Employees
-
More about the company
Date Price Change Volume
25-02-12 0.1900 $ +5.56% 1,000
25-02-11 0.1800 $ -2.70% 21,500
25-02-10 0.1850 $ 0.00% 1,500
25-02-07 0.1850 $ +2.78% 500
25-02-06 0.1800 $ -2.70% 2,000

Delayed Quote Canadian Securities Exchange, February 12, 2025 at 01:48 pm EST

More quotes